Brain volume changes in the first year of illness and 5-year outcome of schizophrenia


Summary
Progressive brain volume changes have been reported in first-episode schizophrenia, but their relationship to the disease process or to other factors remains unclear. We examined such changes in the first year of illness, and related them to 5-year outcome. Progressive brain volume changes, in particular of grey matter, during the first year of illness were found to be significantly associated with clinical and functional outcome 5 years after the first episode. These findings suggest that early dynamic brain volume changes are related to the disease process and predict the longer-term outcome of schizophrenia.

Declaration of interest
None.

METHOD
Our initial study included 34 people with first-episode schizophrenia. After a mean follow-up period of 5.3 years (s.d.=0.8), three patients refused further participation. The present study included the remaining 31 participants (27 men and 4 women), with a mean age of 25.74 years (s.d.=4.88). Before inclusion, participants had used no or little antipsychotic medication: mean lifetime dose 163.85 mg (s.d.=72.26) haloperidol equivalents. All participants received a DSM-IV (American Psychiatric Association, 1994) diagnosis of schizophrenia (26) or schizoaffective disorder (5) and provided written informed consent.

Magnetic resonance images were acquired on a 1.5 Philips NT scanner and obtained at inclusion (T0) and after 1 year (T1). In-house developed software was used to measure mean (s.d.): total brain volume T0=1321.22 ml (108.57) and T1=1306.84 ml (113.66); grey matter T0=687.36 ml (50.29) and T1=668.91 ml (57.20); white matter T0=473.87 ml (64.06) and T1=476.06 ml (60.61);
cerebellar T0=145.79 ml (11.99) and T1=147.04 ml (7.70); frontal lobe T0=291.86 ml (28.70) and T1=288.05 ml (23.11); lateral T0=14.84 ml (6.64) and T1=15.89 ml (7.70); and third ventricle T0=0.84 ml (0.39) and T1=0.88 ml (0.37). Images were checked and corrected manually if necessary. For a description of procedure and segmentation, see Hulshoff Pol et al (2002).

Patients were assessed with the Positive and Negative Syndrome Scale (PANSS; Kay et al, 1987), mean (s.d.) at T0 positive symptoms 18.24 (5.77) and negative symptoms 18.90 (6.55); T1 positive symptoms 12.93 (4.61) and negative symptoms 15.40 (5.20); and T5 (5 years) positive symptoms 14.13 (5.71) and negative symptoms 15.38 (7.13). The Camberwell Assessment of Need (CAN; Phelan et al, 1995) mean (s.d.) was obtained after 2 years of follow up (T2): number of met and unmet needs 5.97 (3.77); and at T5: number of met and unmet needs 9.48 (6.61). In addition, Global Assessment of Functioning (GAF; American Psychiatric Association, 1994) mean (s.d.) 53.61 (21.57); and the assessment whether patients lived independently or not: (yes=17; no=14); were obtained at T5. Negative and positive PANSS symptom scores at T5 were used as measures of clinical outcome. Scores on the CAN, GAF and the assessment whether patients lived independently or not were used as measures of functional outcome.

To assess whether dynamic brain volume changes in the first year predict the 5-year clinical and functional outcome, linear regression analyses were performed with the unstandardised regression coefficient (β) representing the outcome score per millilitre volume change. Brain volume change (T0 to T1) of the various brain structures entered the analyses as predictor variables, with age and intracranial volume as covariates. As progressive brain volume change might have commenced before T0, baseline measures of the brain structures also entered the analyses as covariates. The various clinical and functional outcome scores obtained at T5 entered the analyses as dependent variables separately. Since clinical outcome might be variable initially but could stabilise over time, the same analyses were done with changes in PANSS scores (T1 to T5), as dependent variables. To assess whether clinical decline is progressive, paired-sample t-tests were performed with PANSS scores (T1 to T5) and CAN scores (T2 to T5) as paired variables.
RESULTS

A greater total brain volume decrease in the first year predicted a higher negative symptom score on PANSS (β = −0.1, t = −2.51, P = 0.02) and a lesser likelihood of living independently (β = −0.01, t = −2.29, P = 0.03) at 5-year follow up.

A greater grey matter volume decrease in the first year predicted a higher positive symptom score (β = −0.09, t = −2.29, P = −0.03), a higher negative symptom score (β = −0.16, t = −3.38, P = 0.002) (Fig. 1a), a lower GAF score (β = 0.40, t = 2.79, P = 0.01) and a lesser likelihood of living independently (β = −0.01, t = −3.94, P = 0.001) (Fig. 1b) at T5.

A greater white matter volume increase in the first year predicted higher positive symptom score (β = 0.09, t = 2.29, P = 0.03) at T5.

A greater lateral ventricle volume increase in the first year predicted a greater number of met and unmet needs (β = 1.47, t = 2.82, P = 0.009) (Fig. 1c) as measured with the CAN and a lesser likelihood to live independently (β = −1.0, t = −2.31, P = 0.03) at T5. A greater cerebellar volume decrease in the first year predicted a higher negative symptom score (β = 0.79, t = −2.24, P = 0.03) at T5.

Frontal lobe and third ventricle volume change did not predict outcome. A greater grey matter (β = −0.12, t = −2.8, P = 0.009) and cerebellar (β = 0.68, t = −2.43, P = 0.02) volume decrease in the first year predicted a greater increase in the negative symptom score of the PANSS (T1 to T5). A greater white matter increase (β = 0.19, t = 3.12, P = 0.004) predicted a greater increase in the positive symptom score of the PANSS. There was no significant increase in symptoms as measured with PANSS between T1 and T5, but total CAN scores significantly increased (t = 3.24, df = 27, P = 0.003) between T2 and T5.

DISCUSSION

This study found that early progressive brain volume changes in the first year can predict the 5-year outcome of schizophrenia. Those patients who had the largest decrease in grey matter in the first year had the highest negative symptom scores and were less likely to live independently 5 years after the first evaluation. Thus, it appears that early dynamic brain changes are not only associated with symptomatic outcome but also with functional outcome. Furthermore, these findings suggest that brain changes in the early stages of schizophrenia are related to the disease process and are clinically relevant in determining prognosis, and they emphasise the importance of early intervention in the treatment of schizophrenia, aiming to slow down or stop progressive brain volume loss.

This view is strengthened by another longitudinal magnetic resonance study that examined dynamic brain volume changes in people at very high risk of developing schizophrenia (Pantelis et al., 2003). This study reported progressive grey matter decrease in very-high-risk individuals who developed a psychotic illness within 12 months. None the less, whether these early progressive brain volume changes in prodromal and first-episode schizophrenia are caused by the disease itself or are a consequence of the disease (and its treatment) still remains unanswered. The treatment of schizophrenia should focus on slowing this early progressive brain loss, with the goal of affecting the clinical course favourably.

REFERENCES


